This is a phase II, single-arm, open-label study in subjects with relapsed and/or refractory multiple myeloma (RRMM) comparing Pembrolizumab (Pembro) in combination with Daratumumab (Dara) to the historical control of Daratumumab.
SparkCures ID | 1189 |
---|---|
Trial Phase | Phase 2 |
Enrollment | Information Not Available |
Treatments | |
Tags | |
Trial Sponsors |
|
Trial Collaborators |
|
NCT Identifier |
|
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
Inclusion Criteria Subjects must meet all of the following inclusion and exclusion criteria to participate in the trial.
Exclusion Criteria
Please visit the ClinicalTrials.gov page for historical site information.
View Centers